If so, this would suggest that the status of the TACR1 gene and/or TACR1 receptor could similarly influence the efficacy of this drug treatment in ADHD patients, and that polymorphism(s) of TACR1 could serve as a biomarker for this subgroup of patients. Here, TACR1 is linked to attention deficit-hyperactivity disorder.